Rol' olmesartana v klinicheskoy praktike


Cite item

Full Text

About the authors

G. A Baryshnikova

ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва

Кафедра семейной медицины

S. A Chorbinskaya

ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва

Кафедра семейной медицины

I. I Stepanova

ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва

Кафедра семейной медицины

N. V Chuprova

ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва

Кафедра семейной медицины

References

  1. Munzel T, Sinning C, Post Fю et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40 (3): 180–96, 653–8.
  2. Pahkala K, Heinonen O.J., Lagstrom H. et al. Vascular endothelial function and leisure - time physical activity in adolescents. Circulation 2008; 118 (23): 2353–9.
  3. Brunner H.R. (2002) The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 16 (Suppl. 2): S13–16.
  4. Puchler K, Laies P, Stumpe K. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001; 19: S41–S48.
  5. Oparil S, Williams D, Chrysant S.G. et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
  6. Norwood D, Branch E, Smith B et al. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast 2002; 27: 611–8.
  7. Chrysant S.G., Marbury T.C., Robinson T.D. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild - to - moderate hypertension. J Hum Hypertens 2003; 17: 425–32.
  8. Chrysant S.G., Marbury T.C., Silfani T.N. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006; 11: 135–41.
  9. Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (4-й пересмотр), 2010.
  10. Barrios V, Boccanelli A, Ewald S. et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007; 27: 545–58.
  11. Chrysant S.G., Melino M. et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double - blind, placebo - controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
  12. Kereiakes D.J., Neutel J.M., Punzi H.A. et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007; 7: 361–72.
  13. Neutel J.M., Smith D.H., Silfani T.N. et al. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006; 20: 255–62.
  14. Neutel J.M., Smith D.H., Weber M.A. et al. Use of an olmesartan medoxomil - based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6: 168–74.
  15. Naya M, Tsukamoto T, Morita K. et al. Olmesartan, but not amlodipine, improves endothelium - dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007; 50 (12): 1144–9.
  16. Smith R.D., Yokoyama H, Averill D.B. et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6 (5): 335–42.
  17. Stumpe K, Agabiti-Rosei E, Zielinski T. et al. Carotid intima - media thickness and plaque volume changes following 2-year angiotensin II receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1 (2): 97–106.
  18. Hirohata A, Yamamoto K, Miyoshi T et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010; 55 (10): 976–82.
  19. Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117–8.
  20. Haller H, Ito S, Izzo J.L. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.
  21. Чазова И.Е., Фомин В.В. Управление кардиоренальным синдромом: возможности блокаторов рецепторов ангиотензина II. Фарматека. 2011; 15: 10–4.
  22. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfl ammation. Circulation 2004; 110 (9): 1103–7.
  23. Brunner H.R. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004; 26 (Suppl. A): A28–A32.
  24. Oparil S, Williams D, Chrysant S.G. et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
  25. Brunner H.R., Stumpe K.O., Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419–30.
  26. Zanorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131–4.
  27. De Luis D.A., Conde R, Gonzalez Sagrado M. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. Eur Rev Med Pharmacol Sci 2010; 14: 759–63.
  28. Fabia M.J., Abdilla N, Oltra R. et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25 (7): 1327–36.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).